What question did this study set out to answer?

To examine the inhibitory effect of ticlopidine administration on adenosine diphosphate-induced release of platelet-derived growth factor from circulating human platelets.

January 1, 1989The Journal of Japan Atherosclerosis SocietyOpen Access

The Effect of Ticlopidine on the Release of Platelet-Derived Growth Factor from Platelets

View Full Paper

Ask AI

Bookmark

Why the study?

Does ticlopidine reduce the release of platelet-derived growth factor (PDGF) from platelets in healthy volunteers?

Population

5 healthy male volunteers, mean age 30.0±3.2 years, not taking any drugs affecting platelet function.

Comparison

Ticlopidine 500 mg/day orally for 7 days. vs Baseline (pre-administration values).

Design

Other

Follow-up

7 days

Authors

TST. ShiraishiMinoh City Hospital SMShigeto MorimotoKanazawa Medical University TOToshio OgiharaNihon University

Discussion

Member takes

Implication

May suggest anti-atherosclerotic potential; hypothesis-generating and should not change practice.

Key Points

To examine the inhibitory effect of ticlopidine administration on adenosine diphosphate-induced release of platelet-derived growth factor from circulating human platelets.
Administered 500 mg daily of ticlopidine for 7 days to 5 healthy male volunteers aged 26 to 34 years (mean ± SD: 30.0 ± 3.2 years).
Isolated platelet-rich plasma (4 × 10⁸ platelets/ml) immediately before and after the 7-day regimen, stimulated platelets with 4 μM adenosine diphosphate (ADP), and quantified platelet-derived growth factor (PDGF) using radioimmunoassay.
Ticlopidine administration significantly suppressed 4 μM ADP-induced PDGF release from 4.0 ± 1.3 ng/4×10⁸ platelets down to 0.8 ± 0.2 ng/4×10⁸ platelets (p < 0.05).
The pronounced decline in PDGF secretion indicates a pharmacological mechanism through which ticlopidine can attenuate the progression of atherosclerosis.

Structured PICO

Does ticlopidine reduce the release of platelet-derived growth factor (PDGF) from platelets in healthy volunteers?

Population

5 healthy male volunteers, mean age 30.0±3.2 years (range 26 to 34 years), not taking any drugs affecting platelet function.

Intervention

Ticlopidine 500 mg/day orally (200 mg after breakfast, 200 mg after lunch, 100 mg after dinner) for 7 days.

Comparator

Baseline (pre-administration values).

Outcome

Quantity of platelet-derived growth factor (PDGF) released from platelets induced by adenosine diphosphate (ADP) stimulation.surrogate

Ticlopidine significantly suppresses ADP-induced PDGF release from platelets, suggesting a potential mechanism for inhibiting the development of atherosclerosis.

Cite This Study

Shiraishi et al. (1989) studied this question.

synapsesocial.com/papers/6a94cb36efe1bb9e53efef1c https://doi.org/10.5551/jat1973.17.5_699

View Full Paper

Ask AI

Bookmark

The Effect of Ticlopidine on the Release of Platelet-Derived Growth Factor from Platelets

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

The Effect of Ticlopidine on the Release of Platelet-Derived Growth Factor from Platelets

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider